Explore 3 Stock Ideas & Industry Insights Download Free Report

News

ACCO Brands Director Receives RSU Grant in September 2026

Director Kathleen S. Dvorak filed a Form 4 with the SEC on September 10, 2026, reporting the acquisition of 5,464 Restricted Stock Units in ACCO Brands Corp on September 9, 2026.

Anjali Anand | 10 September 2026

Buckle Inc. Reports Q2 Fiscal 2026 Financial Results

The Buckle, Inc. filed a Form 10-Q with the U.S. Securities and Exchange Commission on September 10, 2026, covering the quarterly period ended August 1, 2026.

Anjali Anand | 10 September 2026

Aldeyra Therapeutics (NASDAQ: ALDX): Reproxalap's Path After a Third FDA Rejection

Aldeyra Therapeutics is a clinical-stage biotechnology company built around reactive aldehyde species (RASP) modulation, an anti-inflammatory approach. Its lead candidate, reproxalap, is a topical treatment aimed at the signs and symptoms of dry eye disease, a large and competitive ophthalmology market. The pivotal moment …

Vinay Lochav | 10 September 2026

Instil Bio (NASDAQ: TIL): A Cash-Rich Biotech Searching for Its Next Program

Instil Bio originally built its identity around tumor-infiltrating lymphocyte (TIL) cell therapies for cancer. After restructuring, the company shifted toward antibody-based oncologyAssetslicensed from China's ImmuneOnco. That strategy unraveled on January 6, 2026, when Instil's subsidiary, Axion Biosciences, announced it would discontinue clinical development of …

Vinay Lochav | 10 September 2026

Instil Bio (NASDAQ: TIL): A Cash-Rich Biotech Searching for Its Next Program

Instil Bio originally built its identity around tumor-infiltrating lymphocyte (TIL) cell therapies for cancer. After restructuring, the company shifted toward antibody-based oncologyAssetslicensed from China's ImmuneOnco. That strategy unraveled on January 6, 2026, when Instil's subsidiary, Axion Biosciences, announced it would discontinue clinical development of …

Vinay Lochav | 10 September 2026

Tevogen Inc (NASDAQ: TVGN): Balancing a T-Cell Platform Against Liquidity Strain

Tevogen Bio, which reports as Tevogen Inc., is developing allogeneic, off-the-shelf CD8+ cytotoxic T-cell therapies through a platform it calls ExacTcell. Its lead candidate, TVGN 489, targets high-risk COVID-19 and related indications such as long COVID, and the company has said a Phase 1 …

Vinay Lochav | 10 September 2026

BiomX Inc (NYSE American: PHGE): The BX004 Phage-Therapy Readout Investors Await

BiomX is a clinical-stage company developing natural and engineered phage therapies, viruses that selectively target and kill specific bacteria. Its lead candidate, BX004, is being studied in a Phase 2b trial for chronic Pseudomonas aeruginosa lung infections in patients with cystic fibrosis, a difficult-to-treat …

Vinay Lochav | 10 September 2026

Senti Biosciences (NASDAQ: SNTI): Inside the Celadon Merger and Its CVR Structure

Senti Biosciences is a clinical-stage company built around "logic-gated" cell and gene therapies, using engineered gene circuits designed to help therapies distinguish cancer cells from healthy tissue. Its most advanced asset, SENTI-202, is an allogeneic CAR-NK cell therapy aimed at acute myeloid leukemia and …

Vinay Lochav | 10 September 2026

Core One Labs (OTC: CLABF): What Remains After the CSE Delisting

Core One Labs is a research-and-development company focused on psychedelic medicine, including biosynthetic production of psilocybin and delivery-technology platforms, alongside interests spanning natural health products and medical clinics. Its shares historically traded in Canada on theCanadian Securities Exchange (CSE)and in the U.S. over-the-counter market. …

Vinay Lochav | 10 September 2026

Outset Medical (NASDAQ: OM): Margin Progress Against a Compressed Valuation

Outset Medical is a medical-technology company built around the Tablo Hemodialysis System, a compact console that integrates water purification, on-demand dialysate production, and connected software. The design targets both acute-care settings and, increasingly, the home, where Outset hopes to expand access to dialysis. The …

Vinay Lochav | 10 September 2026
Support

Hi! How can we help you today?

Loading…